Mereo BioPharma Group plc MREO
Mereo BioPharma Group plc (Nasdaq: MREO) is a rare genetic drug developer. Its lead program, setrusumab (BPS-804/UX143), is in Phase 3 for osteogenesis imperfecta (OI).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| setrusumab (BPS-804/UX143) | osteogenesis imperfecta | antibody | Phase 3 |
| alvelestat (MPH-966) | severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) | small molecule | Phase 2 |
| etigilimab (MPH-313) | oncology (not stated in extract) | antibody | Phase 1 |
Recent results and decisions
- Dec 29, 2025missed Phase 3 ORBIT missed primary endpoint of reduced annualized clinical fracture rate vs placebo (n=159), though BMD secondary endpoint was met with strong statistical significance.
Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.